Chlorogenic Acid as a Model Compound for Optimization of an In Vitro Gut Microbiome-Metabolism Model
Olivier Mortelé,
Elias Iturrospe,
Annelies Breynaert,
Christine Lammens,
Xavier Basil Britto,
Surbhi Malhotra-Kumar,
Philippe Jorens,
Luc Pieters,
Alexander L. N. van Nuijs,
Nina Hermans
Affiliations
Olivier Mortelé
Natural Products and Food-Research & Analysis (NatuRA), University of Antwerp, 2610 Wilrijk, Belgium
Elias Iturrospe
Toxicological Centre, University of Antwerp, 2610 Wilrijk, Belgium
Annelies Breynaert
Natural Products and Food-Research & Analysis (NatuRA), University of Antwerp, 2610 Wilrijk, Belgium
Christine Lammens
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, 2610 Wilrijk, Belgium
Xavier Basil Britto
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, 2610 Wilrijk, Belgium
Surbhi Malhotra-Kumar
Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, 2610 Wilrijk, Belgium
Philippe Jorens
Department of Critical Care Medicine, Antwerp University Hospital, Clinical Pharmacotherapy and Toxicology, University of Antwerp, 2650 Edegem, Belgium
Luc Pieters
Natural Products and Food-Research & Analysis (NatuRA), University of Antwerp, 2610 Wilrijk, Belgium
Alexander L. N. van Nuijs
Toxicological Centre, University of Antwerp, 2610 Wilrijk, Belgium
Nina Hermans
Natural Products and Food-Research & Analysis (NatuRA), University of Antwerp, 2610 Wilrijk, Belgium
It has been believed that the metabolism of xenobiotics occurred mainly by the cytochrome P450 enzyme system in the liver. However, recent data clearly suggest a significant role for the gut microbiota in the metabolism of xenobiotic compounds. This microbiotic biotransformation could lead to differences on activation, inactivation and possible toxicity of these compounds. In vitro models are generally used to study the colonic biotransformation as they allow easy dynamic and multiple sampling over time. However, to ensure this accurately mimics communities in vivo, the pre-analytical phase requires optimization. Chlorogenic acid, a polyphenolic compound abundantly present in the human diet, was used as a model compound to optimize a ready-to-use gut microbiome biotransformation platform. Samples of the in vitro gastrointestinal dialysis-model with colon stage were analyzed by liquid chromatography coupled to high resolution time-of-flight mass spectrometry. Complementary screening approaches were also employed to identify the biotransformation products.
